Adaptive Biotechnologies Corp — Director's Dealing 2020

Dec 31, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptive Biotechnologies Corp (ADPT)
CIK: 0001478320
Period of Report: 2020-12-28

Reporting Person: ROBINS CHAD M (Director, CEO and Chairman)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-28	Common Stock	M	16250	$0.33	Acquired	1794430	Direct
2020-12-28	Common Stock	S	13542	$60.71	Disposed	1780888	Direct
2020-12-28	Common Stock	S	1108	$61.48	Disposed	1779780	Direct
2020-12-28	Common Stock	S	1500	$62.60	Disposed	1778280	Direct
2020-12-28	Common Stock	S	100	$63.41	Disposed	1778180	Direct
2020-12-29	Common Stock	M	16790	$0.33	Acquired	1794970	Direct
2020-12-29	Common Stock	S	8256	$58.87	Disposed	1786714	Direct
2020-12-29	Common Stock	S	6834	$59.42	Disposed	1779880	Direct
2020-12-29	Common Stock	S	1700	$60.73	Disposed	1778180	Direct
2020-12-30	Common Stock	M	16520	$0.33	Acquired	1794700	Direct
2020-12-30	Common Stock	S	7651	$59.20	Disposed	1787049	Direct
2020-12-30	Common Stock	S	8869	$59.65	Disposed	1778180	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-28	Stock Option (Right to Buy)	$0.33	M	16250	Disposed	2021-12-20	Common Stock (16250)	Direct
2020-12-29	Stock Option (Right to Buy)	$0.33	M	16790	Disposed	2021-12-20	Common Stock (16790)	Direct
2020-12-30	Stock Option (Right to Buy)	$0.33	M	16520	Disposed	2021-12-20	Common Stock (16520)	Direct

Footnotes

F1: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020.

F2: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $60.12 to 61.11, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

F3: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $61.14 to 61.74, inclusive.

F4: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $62.14 to 63.13, inclusive.

F5: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $58.21 to 59.20, inclusive.

F6: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $59.21 to 60.01, inclusive.

F7: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $60.26 to 61.05, inclusive.

F8: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $58.48 to 59.46, inclusive.

F9: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $59.49 to 59.99, inclusive.

F10: The options are fully vested and exercisable.